Abstract: Locally advanced prostate cancer is regarded as a very high-risk disease with a poor prognosis. Although there is no definitive consensus on the definition of locally advanced prostate cancer, radical prostatectomy for locally advanced prostate cancer as a primary treatment or part of a multimodal therapy has been reported. Robot-assisted radical prostatectomy is currently carried out even in high-risk prostate cancer because it provides optimal outcomes. However, limited studies have assessed the role of robotassisted radical prostatectomy in patients with locally advanced prostate cancer. Herein, we summarize and review the current knowledge in terms of the definition and surgical indications of locally advanced prostate cancer, and the surgical procedure and perisurgical/oncological outcomes of robot-assisted radical prostatectomy and extended pelvic lymphadenectomy for locally advanced prostate cancer.
Introduction
PCa is the most prevalent male malignancy in many regions of the world, and it represents the second most common cause of cancer-related death in the USA and Europe. 1 Despite the introduction and diffusion of PSA-based screening that has dramatically increased the proportion of patients diagnosed with low-risk PCa, approximately 10% of contemporary patients still present with locally advanced features and a potentially lethal course. 2 Locally advanced PCa is regarded as a very high-risk disease with not only biochemical recurrence, but also with metastasis and death. 2, 3 There is currently no consensus regarding the optimal treatment of patients with locally advanced PCa. 3 Nevertheless, open or laparoscopic radical prostatectomy for locally advanced PCa as a primary treatment or as part of a multimodal therapy in combination with additional treatments, such as RT and ADT, has been reported. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Long-to intermediateterm retrospective series have shown CSS rates of >60% at 15 years and OS rates of >75% at 10 years, despite the higher likelihood of biochemical recurrence and secondary therapy. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Even for cT3b-T4 disease, PCa cohort studies showed a 10-year CSS of >87% and an OS of 65%. [12] [13] [14] [15] [16] EAU guidelines now support a role for radical prostatectomy in select patients with locally advanced PCa as one treatment option within a multimodality approach. 3 RALP currently represents the most commonly carried out surgical procedure in men with localized PCa. 17 Recent reviews comparing RALP with open radical prostatectomy have shown similar to superior rates of positive surgical margins and biochemical recurrence with decreased blood loss and need for blood transfusion. 18, 19 Although radical prostatectomy is an important therapeutic option for select patients with locally advanced PCa, the role of RALP has not been well investigated. The present review evaluates the indications, technical aspects and short-term outcomes of RALP in locally advanced PCa. The aim of the present review was to investigate whether RALP can be safely offered to such patients.
risk PCa seems to respond fairly well after curative therapy, a subgroup of the disease, referred to as "locally advanced" or "very high-risk," persists despite treatment. However, there is no definitive consensus on a uniform definition of locally advanced or very high-risk PCa; therefore, several studies have attempted to better stratify patients within this heterogeneous high-risk PCa group (Table 1) . [20] [21] [22] [23] [24] [25] Unfortunately, due to the lack of an established definition, studies evaluating locally advanced PCa include heterogeneous populations and show wide variability in outcomes.
Indications and objectives
In cases of locally advanced disease, the traditional consensus has been that the oncological outcomes of radical surgery do not surpass those of radiation therapy and/or androgen deprivation therapy because of the risk of subclinical metastatic disease and elevated rates of positive surgical margins. Hence, the role and indications of radical surgery as a primary treatment remain uncertain. However, a recent study on a series of men with clinical T3 PCa revealed comparable CSS rates with radical surgery versus radiation or hormonal treatment. 11, 26, 27 Furthermore, some recent reports suggest that surgery has expanded its indications to include locally advanced PCa, and that it yields long-term cancer control that is comparable with that of radiation and hormone combined therapy, and greater than that of radiation alone. 11, 28, 29 More recently, local radical treatment, including surgical intervention, has been considered appropriate even in metastatic disease in light of technological advancements and refinements in surgical techniques, such as robotic surgery. [30] [31] [32] Although the outcomes of RALP for high-risk PCa have been reported and reviewed, many of the reports used the D'Amico criteria for risk classification that could include patients (cT2c factor only) with relatively favorable prognoses. 33, 34 Therefore, in the present review, we discuss the studies that treated patients with clinical-pathological stage T3 or higher locally advanced PCa.
In 2009, Ham et al. published a study of 121 patients with locally advanced PCa that evaluated the feasibility of RALP as a primary treatment. 35 Casey et al. assessed 35 RALP patients with pathologically advanced (pT3 and higher) disease. 36 In 2013, Vora et al. reported a retrospective study of 140 RALP patients with pT3 and higher. 37 Koo et al. assessed the feasibility of RALP-PLND in 53 patients aged ≥70 years with very high-risk PCa features according to NCCN criteria by comparing outcomes with 101 patients with high-risk PCa (NCCN). 38 In a recent report from three high-volume European centers, 94 patients with locally advanced PCa as defined by clinical stage T3 or higher were treated with RALP and ePLND. 39 All of the aforementioned studies were retrospective clinical data analyses.
Surgical procedures and perisurgical outcomes
In all of the reports, the RALP procedures were carried out through a six-port transperitoneal approach using the Da Vinci Si Surgical System (Intuitive Surgical, Sunnyvale, CA, USA). Wide resection of the surrounding prostate should be achieved for locally advanced PCa. In one study, a detailed pathological analysis of a prostatectomy specimen showed that the median extracapsular extension distance was 2.4 mm (0.05-7.0 mm). 40 The 90 th percentile distance was 5.0 mm. Therefore, ACR Appropriateness Criteria suggests that clinical target volume in external beam radiation therapy for highrisk patients with PCa should be expanded up to 7 mm for posterolateral lesions. 41 The details of surgical technique that resulted in a large amount of tissue surrounding the pathological specimen were described by Gandaglia et al. as follows. 39 The Denonvilliers' fascia was incised during the isolation and dissection of the seminal vesicles. The perirectal fatty tissue was entered and dissected between the rectum and the posterior aspect of the Denonvilliers' fascia. The Denonvilliers' fascia was completely dissected and left on the posterior surface of the seminal vesicles. They dissected the lateral extrafascia to the levator ani fascia. The neurovascular bundles were clipped and transected below the Denonvilliers' fascia. Other procedures, such as bladder detachment, endopelvic fascia incision, bladder neck incision, ligation of the dorsal venous complex, apical dissection, posterior reconstruction and urethrovesical anastomosis were carried out according to previously described techniques. 42, 43 For NS, Casey et al. 36 and Koo et al. 38 carried out NS in a greater proportion of their patients, and showed that NS, either bilateral or unilateral, was not associated with increased positive margins in patients with locally advanced PCa. Lavery et al. studied the performance of NS in patients with high-risk PCa. 44 In that study, although 71 patients with pathologically advanced (pT3 and higher) findings showed a high rate of positive margins (46.5%), the authors concluded that there is no correlation between NS and these higher rates of PSM or biochemical recurrence. However, in general as mentioned above, a non-NS procedure was deemed preferable in patients with biopsy-proven seminal vesicle invasion, extracapsular extension on magnetic resonance imaging, or high-volume, high-grade disease. 39 For lymph node dissection, PLND in patients undergoing radical prostatectomy for PCa remains a topic of controversy. 45, 46 ePLND included the intrapelvic area (obturator, internal and external iliac) and the common iliac area up to the ureteric crossings. This template would allow for the correct staging of up to 94% of patients with node-positive disease, and for the removal of all of the metastatic nodes in approximately 75% of cases. 47 Although it represents the most accurate staging procedure, ePLND is associated with Multiple risk factor (PSA >20, GS 8-10, cT3-4) Joniau et al.
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GS 8-10 + risk factor (PSA >20 and/or cT3-4) Sundi et al.
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GS 5 or ≥5 cores with GS 8,9 or multiple risk NCCN guideline 20 T3b-T4 EAU guideline worse intraoperative and perioperative outcomes, whereas its direct therapeutic effect remains unclear. 45 No confident consensus exists as to its benefits for oncological purposes due to a lack of high-level evidence. 45, 46 In a review of comparative evaluation of PLND by surgical methods, robotic PLND can be carried out effectively and safely. 48 The overall number of nodes removed, the likelihood of node positivity, and the types and rates of complications of PLND are similar to pure laparoscopic and open retropubic procedures. In contrast, the ePLND was shown to prolong the RALP by 20 min in comparison with limited PLND restricted to obturator fossa lymph node dissection, even in a single high-volume surgeon series. 49 Nevertheless, PLND is considered the best method for lymph node staging, and ePLND can play an important role in locally advanced PCa. Just three studies reported consistent use of ePLND in patients with locally advanced PCa ( Table 2 ). Other studies did not specify the template of dissection or carry out limited LND, and the reasons for omitting or limiting LND were not stated. The mean/median lymph node yield from these ePLND studies was 15.9-18.6 nodes. Overall lymph node-positive rates ranged from 19% to 37%, with the highest rates occurring in the ePLND cohorts. The complications by ePLND are shown in Table 2 , although reporting methods varied. The rate of symptomatic lymphocele in the ePLND series was approximately 3%.
These investigations support the feasibility of an anatomically defined ePLND carried out by a skilled robotic surgeon. In this context, it should be noted that individual surgeon experience and commitment rather than the particular surgical approach itself has a significant impact on the ePLND and on the number of nodes removed.
Perisurgical outcomes
Some of the known advantages of RALP compared with open radical prostatectomy are rapid convalescence, reduced bleeding and decreased analgesic intake. The risk of blood transfusion is much higher in ORP than in RALP. 50 The risk of perioperative complications in RALP was reportedly 7% greater than that in ORP. 51 On review of locally advanced PCa studies, mean/median blood loss and operative time ranged from 200 to 431 mL, and from 200 to 271 min, respectively. Mean hospital stay ranged from 1.6 to 5.8 days, and the rate of complications ranged from 8.3% to 29% (Table 3) . These outcomes were compatible with prior findings among low-risk patients who underwent RALP more regularly than did locally advanced patients. Koo et al. showed that RALP for high-and very high-risk elderly patients resulted in a comparable convalescence with ORP, in which surgery complications were expected to be high. 38 
Functional outcomes
For oncological safety, extended and wide resection is expected in surgical procedures for locally advanced PCa, which might result in disrupted urinary and sexual function. The advantages of RALP carried out by skilled surgeons include tissue magnification and recognition, and tridimensional vision, which can result in improved urinary continence recovery, even in the context of extended wide resection in locally advanced PCa.
Studies of patients with locally advanced PCa have shown heterogeneous continence outcomes after RALP. Casey et al. reported satisfactory outcomes, with 100% continence at postoperative 1 year. 35 Gandaglia et al. reported that 64% of his cohort was using one or no pads daily at 12 months after RALP. 39 The relatively low continence recovery rates might be related to the inclusion of men with locally advanced disease who were treated with non-nerve sparing approaches. Koo et al. had inferior results using a no-pad definition (33% of continence recovery at 12 months). 38 However, the latter study involved an elderly population (aged >70 years), and age is recognized to be a paramount variable in continence recovery (Table 3) .
Pathological outcomes in surgical specimens
A recent systematic review and meta-analysis assessed the PSMs of studies comparing ORP and RALP in high-risk PCa, showing a decreased risk of PSMs and BCR in RALP. 19 When addressing high-risk PCa using the D'Amico classification, the reported rate of PSMs in RALP ranged from 16% to 58%. With regard to locally advanced PCa in which a greater extracapsular extension is expected, Mitchell et al. reported that the positive margin rate exceeded 50% in patients with cT3 disease who were treated with ORP. 52 The rates of PSMs in RALP ranged from 20% to 60% (Table 4) . Gandaglia et al. showed a relatively lower rate of PSMs, which might be associated with wide resection based on the superior visualization of the prostate and apex secondary to tissue magnification, reduced intraoperative bleeding, and tridimensional vision. 39 Accurate histopathological grading is an important determinant in the staging of disease and management planning. However, a downgrading rate of 20% and an upgrading rate of 9% to 27% have been reported for cT3 disease. 11, 53 Koo et al. found that 4% of their very high-risk patients fell into the intermediate risk group according to histopathological evaluation. 38 
Oncological outcomes
Current RALP studies of locally advanced PCa report BCR rates ranging from 18.5% to 28.6% (Table 4) . Although some of the reviewed articles did not mention the PSA cut-off that was used, most of them considered a PSA >0.2 ng/mL to be a marker for BCR. Most series involved relatively short-term observation. In terms of survival analysis, estimates of CSS and OS are a major concern for patients with locally advanced PCa; however, they were scarcely reported in the current series. No long-term studies on CSS or OS in a locally advanced PCa cohort treated with RARP were found.
Discussion
In the present review, locally advanced PCa is characterized by extracapsular extension (T3a), invasion of the seminal vesicles (T3b) or invasion of other adjacent organs (T4) experientially. Because of varying definitions of locally advanced PCa and the range of quality of the published reports, it is difficult to compare outcomes across the literature. Furthermore, while the existing data on robotically treated locally advanced PCa remain limited, those studies reported acceptable perioperative and oncological outcomes in patients with locally advanced PCa who underwent robot-assisted surgery. In particular, a recent investigation in three high-volume European institutions provided better data on the risk of recurrence. At the 3-year follow up, more than two out of three patients were free of BCR. 39 In addition, the CR-free survival rates at this time exceeded 95%. These results support the oncological safety of RALP when carried out by a skilled robotic surgeon, with wide resection and ePLND as a primary treatment for locally advanced PCa.
One major benefit of radical surgery in patients with locally advanced PCa involves the evaluation of the surgical specimen. Accurate staging in advanced disease is an important determinant of the future management strategy. Considering that surgery including ePLND is the only treatment that allows for restaging, the surgery might prevent patients who were overdiagnosed presurgically from being unnecessarily exposed to the risk of adverse effects inherent to adjuvant therapy. Next, the post-surgical PSA value might become a surrogate for complete resection, even in pathologically advanced disease. A zero PSA value might allow adjuvant therapy to be avoided, even in patients with PSMs and/or positive lymph nodes.
The diagnosis potential of ePLND is also emphasized. Radiographic diagnosis of pelvic lymph nodes tends to be inaccurate when using the conventional methods, such as magnetic resonance imaging or computed tomography scan. A relatively high rate of men with pN1 (approximately 20-40%) has been observed in patients with locally advanced PCa. Although patients who were misdiagnosed as having positive nodes might have immediately started systemic therapy if ePLND had not been carried out, those without evidence of lymph node metastasis can be observed until an adjuvant therapy becomes necessary. In contrast, patients with nodal metastasis proven by ePLND can be immediately considered for early adjuvant therapy. 54 In lymphadenopathy patients, the outcomes of 50 patients with cN + were compared with those of 252 patients with pN1 and cN0 at preoperative staging, and cN + was not a significant predictor of CSS. 55 The survival benefits of ePLND remain controversial; however, a recent review suggested that the debulking of the primary tumor with PLND could improve CSS and OS by means of regional disease control. 19 RALP and ePLND could be considered as the standard for accurate nodal staging and local disease control, especially for patients with lymph node metastasis.
Postoperative RT as one of the multimodal therapies for locally advanced PCa confers excellent long-term cancer control. However, whether adjuvant RT or wait-and-see strategy has been discussed. Meta-analysis showed adjuvant RT results in greater benefits of biochemical progression-free survival, clinical progression-free survival, hormone-free survival and 10-year metastasis-free survival in comparison with a wait-and-see strategy, there is no difference in OS. 56 In contrast, adjuvant RT showed significantly increased genitourinary toxicity, urinary stricture rates and urinary incontinence. One of the primary concerns regarding the use of adjuvant RT is the concern of overtreatment and potential side-effects. Therefore, patient selection for adjuvant RT or salvage RT is important. Results from ongoing randomized trials will help to determine the role of salvage RT compared with adjuvant RT. 57, 58 In the near future, the selection might be improved with novel molecular imaging. The 68 Ga-prostate-specific membrane antigen positron emission tomography computed tomography can identify lesions in >50% of patients with low PSA (<1.0 ng/mL) biochemical recurrence. 59 The test might help identify patients with local pelvic recurrences or metastatic recurrences.
Neoadjuvant ADT might improve prognosis in high-risk patients, and has many potential benefits, including the ability to achieve local control, downstage localized or locally advanced tumors and eradicate microscopic metastatic disease. 60 However, pathological results might be affected in patients who receive neoadjuvant androgen deprivation therapy. This includes a possible population of overdiagnosed patients, who might actually be able to avoid ADT. Furthermore, PSA values might not serve as a surrogate marker of residual/systemic disease in the context of low androgens. Further studies and long-term evaluations are required to identify the effectiveness of neoadjuvant ADT.
Conclusion
Increasing evidence suggests that RALP and extended pelvic lymph node dissection might improve survival, even in nodepositive PCa. In addition, RALP should be considered as a primary therapy in a multimodal approach to treating locally advanced PCa.
Further studies are requires to confirm the effectiveness of RALP at long-term follow up in this clinical scenario.
